Marshall Wace, LLP Editas Medicine, Inc. Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

A detailed history of Marshall Wace, LLP transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 63,759 shares of EDIT stock, worth $79,698. This represents 0.0% of its overall portfolio holdings.

Number of Shares

63,759

Previous 449,153 85.8%

Holding current value

$79,698

Previous $2.1 Million 89.65%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.39 - $5.96 $1.31 Million - $2.3 Million	-385,394 Reduced 85.8%	63,759 $217,000
Q2 2024 Aug 14, 2024	SELL	$4.67 - $7.28 $1.6 Million - $2.49 Million	-342,167 Reduced 43.24%	449,153 $2.1 Million
Q1 2024 May 15, 2024	SELL	$7.03 - $11.07 $2.25 Million - $3.54 Million	-319,882 Reduced 28.79%	791,320 $5.87 Million
Q4 2023 Feb 14, 2024	SELL	$6.25 - $11.11 $6.77 Million - $12 Million	-1,083,604 Reduced 49.37%	1,111,202 $11.3 Million
Q3 2023 Nov 14, 2023	SELL	$6.92 - $9.31 $4.45 Million - $5.99 Million	-643,511 Reduced 22.67%	2,194,806 $17.1 Million
Q2 2023 Aug 14, 2023	BUY	$6.36 - $11.47 $18.1 Million - $32.6 Million	2,838,317 New	2,838,317 $23.4 Million
Q4 2022 Feb 14, 2023	BUY	$8.32 - $13.21 $198,573 - $315,283	23,867 New	23,867 $211,000
Q2 2022 Aug 15, 2022	SELL	$9.99 - $21.35 $177,072 - $378,428	-17,725 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$14.08 - $27.63 $5.19 Million - $10.2 Million	-368,902 Reduced 95.42%	17,725 $337,000
Q4 2021 Feb 14, 2022	BUY	$26.55 - $40.57 $10.3 Million - $15.7 Million	386,627 New	386,627 $10.3 Million
Q1 2019 May 14, 2019	SELL	$19.43 - $26.41 $347,894 - $472,871	-17,905 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$18.19 - $31.79 $325,691 - $569,199	17,905 New	17,905 $408,000

Others Institutions Holding EDIT

# of Institutions

240

Shares Held

56.5M

Call Options Held

410K

Put Options Held

394K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $85.9M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Editas Medicine, Inc. Transaction History